Update on phase III CONTACT-03 trial evaluating cabozantinib + atezolizumab in patients with previously treated advanced renal cell carcinoma
Exelixis, Inc. announced that the phase III CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS)
CONTACT-03 evaluated cabozantinib (Cabometyx) in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during or after immune checkpoint inhibitor therapy (either combination or monotherapy).
The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent, and no new safety signals were identified with the combination. Detailed findings will be presented at an upcoming medical meeting.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins